Functional Capacity Assessment for Schizoaffective Disorder

Functional Capacity Assessment for Schizoaffective Disorder, Sina OT

Schizoaffective disorder is a serious, chronic psychiatric condition that combines the psychotic features of schizophrenia with the significant mood disturbance of either bipolar disorder or major depressive disorder. It is one of the most functionally impairing conditions in the psychosocial disability spectrum, producing a burden of disability that, in many cases, exceeds that of either schizophrenia or mood disorder alone. For people with schizoaffective disorder who meet the NDIS substantially reduced functional capacity threshold, a comprehensive Functional Capacity Assessment is the primary evidence document for NDIS access and planning.

What is schizoaffective disorder?

Schizoaffective disorder is a psychotic disorder classified in DSM-5 within the schizophrenia spectrum and other psychotic disorders. It is distinguished from schizophrenia by the presence of significant, prominent mood disorder symptoms that are present for the majority of the total duration of the illness. It is distinguished from bipolar disorder with psychotic features and from major depressive disorder with psychotic features by the requirement that psychotic symptoms occur for a period of at least two weeks in the absence of mood symptoms at some point during the illness.

In practical terms, a person with schizoaffective disorder experiences both the psychotic symptoms of schizophrenia — hallucinations, delusions, disorganised thinking and negative symptoms — and the mood symptoms of either bipolar disorder or major depressive disorder, with each type of symptom present for substantial portions of the illness course. The two symptom domains interact and compound each other, producing a clinical picture that is often more severe and more difficult to manage than either psychosis or mood disorder alone.

DSM-5 diagnostic criteria

Under DSM-5, a diagnosis of schizoaffective disorder requires that all four of the following criteria are met.

  • Criterion A: An uninterrupted period of illness during which there is a major mood episode — either a major depressive episode or a manic episode — concurrent with the presence of two or more of the Criterion A symptoms of schizophrenia, which include delusions, hallucinations, disorganised speech, grossly disorganised or catatonic behaviour and negative symptoms such as diminished emotional expression or avolition.
  • Criterion B: Delusions or hallucinations are present for two or more weeks in the absence of a major mood episode at some point during the lifetime of the illness. This criterion distinguishes schizoaffective disorder from a mood disorder with psychotic features, in which psychotic symptoms occur only during mood episodes.
  • Criterion C: Symptoms that meet the criteria for a major mood episode are present for the majority of the total duration of the active and residual phases of the illness. This criterion distinguishes schizoaffective disorder from schizophrenia, in which mood episodes may occur but are not present for the majority of the illness course.
  • Criterion D: The disturbance is not attributable to the physiological effects of a substance or another medical condition.

The two subtypes: bipolar type and depressive type

DSM-5 specifies two subtypes of schizoaffective disorder based on the type of mood episode that forms part of the presentation.

Subtype

Clinical features

Bipolar type

The presentation includes at least one manic episode. Major depressive episodes may also occur. The bipolar type is associated with a more episodic course. During manic phases, the person may present with grandiose or persecutory delusions, elevated or irritable mood, markedly increased energy, decreased need for sleep, impulsivity and disorganised behaviour. Psychotic symptoms can be present both during and between mood episodes.

Depressive type

The presentation includes only major depressive episodes as the mood component, with no manic or hypomanic episodes. The depressive type tends toward a more chronic and less episodic course. The combination of psychotic symptoms and severe depression produces a particularly high burden of disability, with profound effects on motivation, energy, self-care and daily functioning.

How schizoaffective disorder differs from related conditions

Schizoaffective disorder occupies a diagnostic position between schizophrenia and the mood disorders. Understanding these distinctions is relevant for NDIS documentation because the specific clinical features that distinguish schizoaffective disorder from related conditions — particularly the persistence of psychotic symptoms outside of mood episodes — have direct implications for the functional impairment profile and the NDIS evidence requirements.

Condition

Key distinguishing feature from schizoaffective disorder

Schizophrenia

Schizophrenia does not have prominent mood symptoms for the majority of the illness course. If mood episodes occur, they are brief relative to the total duration of the illness.

Bipolar disorder with psychotic features

In bipolar disorder with psychotic features, psychotic symptoms occur only during mood episodes — during a manic or depressive episode. There is no period of psychotic symptoms lasting two or more weeks without a mood episode.

Major depressive disorder with psychotic features

Psychotic symptoms occur only during depressive episodes. As above, there is no two-week period of psychotic symptoms independent of mood.

 

What is schizophrenia?

Schizophrenia is a serious, chronic psychiatric condition characterised by the presence of psychosis — a significant disruption to a person’s connection with reality — combined with negative symptoms and cognitive impairment. It affects approximately 1 per cent of the population globally and typically emerges in late adolescence or early adulthood, with men generally receiving a diagnosis in their late teens to early twenties and women in their late twenties to early thirties.

Under DSM-5, a diagnosis of schizophrenia requires the presence of two or more of the following five symptoms, at least one of which must be from the first three, persisting for a significant portion of time over a one-month period, with continuous signs of the disturbance persisting for at least six months.

  • Delusions — fixed false beliefs that are firmly held despite evidence to the contrary. Delusions may be persecutory (the belief that one is being monitored, followed or harmed), grandiose (the belief that one has exceptional abilities, wealth or importance), referential (the belief that ordinary events in the environment carry special personal meaning) or other types.
  • Hallucinations — perceptions that occur without a corresponding external stimulus. In schizophrenia, auditory hallucinations — hearing voices — are the most common. The voices may comment on the person’s behaviour, issue commands, argue with each other or address the person directly.
  • Disorganised speech — a reflection of disorganised thinking, in which the logical connection between ideas is loosened or lost. The person’s speech may jump unpredictably between unrelated topics, use words in unconventional ways or become incoherent.
  • Grossly disorganised or catatonic behaviour — ranging from unpredictable agitation to complete unresponsiveness, including bizarre posturing, rigid immobility, purposeless movements or extreme negativism.
  • Negative symptoms — a reduction or absence of normal functions, including flat affect (reduced emotional expressiveness), avolition (markedly reduced motivation and goal-directed behaviour), alogia (poverty of speech) and anhedonia (reduced capacity for pleasure).

Schizophrenia is a lifelong condition. It does not arise from weakness of character, poor parenting or personal failure. It has a well-established neurobiological basis involving structural and functional differences in brain circuitry, particularly in regions involved in dopamine regulation. With appropriate treatment and support, many people with schizophrenia can live in the community and achieve a meaningful quality of life, though the condition typically requires long-term clinical management.

It is important to understand that schizophrenia is not the same as a split or multiple personality, a misconception that persists widely in the community. The term schizophrenia refers to a disruption in the normal integration of thought, perception and behaviour — not a division into separate personalities.

What is schizoaffective disorder and how does it differ from schizophrenia?

Schizoaffective disorder is a condition that shares the psychotic features of schizophrenia but is distinguished by the persistent and prominent presence of significant mood disorder — either bipolar or depressive — for the majority of the illness course. Understanding the difference between schizophrenia and schizoaffective disorder requires understanding what makes them clinically distinct.

In schizophrenia, mood episodes may occur but they are brief relative to the total duration of the illness. The core clinical picture is dominated by psychosis. In schizoaffective disorder, mood symptoms are not incidental — they are present for the majority of the illness course and represent a fundamental part of the clinical picture alongside the psychosis. The person experiences both psychotic symptoms and major mood episodes as persistent, central features of their condition.

The second key distinction is that in schizoaffective disorder, psychotic symptoms must be present for at least two weeks without a major mood episode at some point in the illness history. This separates schizoaffective disorder from bipolar disorder with psychotic features and from major depressive disorder with psychotic features, in which psychotic symptoms only ever occur during mood episodes.

In practice, schizoaffective disorder produces a more complex and often more disabling clinical picture than either schizophrenia or mood disorder alone, because the person must manage both the psychotic and the mood dimensions of the illness simultaneously and because the two symptom domains interact and compound each other.

The schizophrenia spectrum: where schizoaffective disorder fits

Under DSM-5, schizoaffective disorder is classified within the Schizophrenia Spectrum and Other Psychotic Disorders chapter. This spectrum encompasses a range of conditions characterised by the presence of psychosis — a disruption in the person’s connection with reality. Understanding where schizoaffective disorder sits within this spectrum, and how it differs from the other conditions on it, is clinically important because the functional profile and NDIS documentation requirements differ across these conditions.

Condition on the spectrum

Key distinguishing features

Schizophrenia

Persistent psychotic symptoms lasting six months or more. No prominent mood episodes for the majority of the illness course. DSM-5 removed the historical subtypes (paranoid, disorganized, catatonic, undifferentiated, residual) as they had poor diagnostic reliability and did not predict treatment response. DSM-5 now uses a dimensional approach based on the severity of individual symptom domains.

Schizoaffective disorder

Persistent psychotic symptoms plus prominent mood episodes (manic or depressive) that are present for the majority of the illness course. Two subtypes: bipolar type and depressive type.

Schizophreniform disorder

Psychotic symptoms meeting schizophrenia criteria but lasting between one and six months. May resolve, or may progress to a diagnosis of schizophrenia or schizoaffective disorder.

Brief psychotic disorder

Sudden onset of psychotic symptoms lasting less than one month. Often triggered by significant stress.

Delusional disorder

Persistent delusions without the other core symptoms of schizophrenia. Hallucinations are absent or not prominent. Functioning outside the delusional system may be relatively preserved.

 

The old DSM-IV subtypes: paranoid, disorganized, catatonic and others

Before the release of DSM-5 in 2013, schizophrenia was divided into five diagnostic subtypes based on the predominant symptoms at the time of diagnosis. These subtypes — paranoid, disorganized, catatonic, undifferentiated and residual — were eliminated in DSM-5 because they had limited diagnostic stability (the same person’s subtype often changed over time), low inter-rater reliability (different clinicians often reached different subtype diagnoses) and poor validity (the subtypes did not predict treatment response or long-term course). DSM-5 replaced them with a dimensional approach that rates the severity of each symptom domain individually.

Despite their removal from DSM-5, the old subtype terms continue to be used in clinical settings, in community language and in documentation from treating clinicians, particularly where the assessment predates 2013 or where the clinician is trained under DSM-IV. Families and support coordinators frequently encounter these terms. Understanding what they describe remains relevant.

Former DSM-IV subtype

Clinical features — still relevant as a symptom description

Paranoid type

Dominated by prominent persecutory or grandiose delusions and auditory hallucinations. Cognitive functioning and affect were relatively better preserved than in other subtypes. People with a paranoid presentation may appear relatively functional on the surface while holding firmly fixed beliefs about persecution by neighbours, government agencies, family members or other specific parties. The functional impact of paranoid symptoms in daily life is addressed in detail in the next section.

Disorganized type (also called hebephrenic)

Characterised by disorganized speech and behaviour with flat or inappropriate affect. The person may speak in ways that are difficult to follow, engage in purposeless activity and present with an incongruous emotional response to situations. This subtype often produces severe functional impairment in self-care, daily task management and communication. Hallucinations and delusions may be present but are not the dominant feature.

Catatonic type

Characterised by marked disturbances in motor behaviour, which may include stupor (markedly reduced responsiveness), rigidity, negativism (opposition to instructions or attempts to be moved), unusual posturing held for extended periods and episodes of purposeless excessive motor activity (catatonic excitement). Catatonia can also occur in the context of mood disorders and other medical conditions. It remains a recognised clinical specifier in DSM-5 rather than a subtype.

Undifferentiated type

A mixed presentation that did not fit clearly into the paranoid, disorganized or catatonic categories. The person had active psychotic symptoms but without the clear predominance of one symptom cluster that characterised the other subtypes.

Residual type

Used to describe a phase where the person no longer had prominent positive symptoms (delusions and hallucinations had reduced or resolved) but continued to experience significant negative symptoms including flat affect, avolition, social withdrawal and poverty of speech. The residual phase often represents the most functionally disabling long-term state of the illness.

 

Types of psychosis: paranoid, disorganized and negative symptom presentations

Psychosis is not a single uniform experience. The functional impact of psychotic symptoms varies significantly depending on the type and content of the symptoms present. The Functional Capacity Assessment must specifically document the type of psychotic symptoms the person experiences and how each type affects their daily functioning.

Paranoid psychosis

Paranoid psychosis is characterised by persecutory beliefs — the conviction that specific individuals, organisations or agencies are conspiring to harm, monitor, follow, poison or otherwise act against the person. The persecutory content is often specific and elaborated. The person may believe their neighbours are monitoring them through listening devices, that food or water is being poisoned, that family members have been replaced by imposters or that government agencies are tracking their movements.

The functional impact of paranoid psychosis on daily life is profound and operates through the behaviour that the beliefs generate. A person with paranoid beliefs about their neighbours may be unable to leave their home, may block doors and windows, may refuse services and visitors and may engage in agitated, defensive or aggressive behaviour in response to perceived threats that exist only within the psychotic framework. This creates direct implications for housing stability, tenancy management, community access, service engagement and personal safety.

Paranoid psychosis and housing: specific challenges

The intersection between paranoid psychosis and housing is one of the most clinically significant functional consequences of the condition and one that is frequently insufficiently documented in NDIS assessments. A person with active paranoid psychosis relating to their neighbours or living environment may:

  • Refuse to allow maintenance workers, inspectors or housing officers into the property, resulting in a pattern of unaddressed maintenance issues that accumulates into a tenancy breach
  • Damage the property in response to perceived threats — blocking vents, covering windows, reinforcing doors, removing fittings believed to contain surveillance equipment
  • Make repeated complaints about neighbours or other parties based on delusional content, generating a pattern of conflict that strains the tenancy relationship with the housing provider
  • Engage in behaviours at night related to the paranoid beliefs — noise, disturbance, confrontations — that generate neighbourhood complaints and formal tenancy breach notices
  • Refuse to pay rent based on a delusional belief that the landlord or housing authority is acting against them, resulting in rent arrears and eviction proceedings
  • Abandon the property suddenly during an acute episode based on a belief that the environment is dangerous, losing the tenancy by abandonment

Each of these consequences is a direct functional result of the psychiatric condition, not a lifestyle choice. The Functional Capacity Assessment must document these specific events, their clinical basis in the paranoid presentation and the support that would be required to prevent their recurrence. This documentation forms the clinical foundation for NDIS funding of support that enables housing maintenance and tenancy sustainability.

Disorganized and negative symptom presentations

In presentations where disorganized thinking and negative symptoms are the dominant features, the functional impairment operates differently from paranoid psychosis. Rather than distress and defensive behaviour in response to perceived threats, the person with predominantly disorganized or negative symptom presentation experiences a progressive inability to initiate, organise and complete the basic tasks of daily life.

Household management — cleaning, managing rubbish, maintaining hygiene in the living space — frequently deteriorates significantly when avolition, disorganization and self-neglect are the predominant features. A tenancy can be lost not because of conflict with neighbours or landlord but because the property has deteriorated to an extent that constitutes a breach of the tenancy agreement. Property damage in this context is not the result of agitated or aggressive behaviour but of progressive neglect, inability to initiate repairs and, in some cases, fire hazard from disorganised living conditions.

The Functional Capacity Assessment must document the specific functional impairment in household management, the clinical reasons for that impairment and the level and type of support required to maintain the property to an acceptable standard.

Medication non-adherence: why it happens and what it means functionally

Non-adherence to prescribed medication is one of the most clinically significant factors in the functional course of schizophrenia and schizoaffective disorder. Estimated rates of medication non-adherence in people with schizophrenia spectrum conditions range from 50 to 75 per cent over time. Understanding why non-adherence occurs is essential for the Functional Capacity Assessment because it directly affects the functional picture, the support requirements and the housing and social stability of the person.

Reasons for medication non-adherence

  • Lack of insight (anosognosia): a neurologically based impaired awareness of one’s own illness, distinct from denial. A person with anosognosia genuinely does not believe they are unwell and therefore sees no reason to take medication. This is not a choice — it is a symptom of the illness itself.
  • Medication side effects: antipsychotic medications frequently cause distressing side effects including weight gain, metabolic changes, sedation, extrapyramidal effects (muscle stiffness, restlessness, involuntary movements) and sexual dysfunction. These side effects are a major driver of voluntary discontinuation.
  • Cognitive impairment: the memory, attention and executive functioning difficulties associated with schizophrenia spectrum conditions directly impair the person’s capacity to manage a reliable medication routine — remembering to take medication, managing prescriptions and coordinating pharmacy attendance.
  • Delusional beliefs about medication: some people hold specific delusional beliefs that the medication is harmful, poisoned or part of a system of control, making adherence impossible without addressing the underlying psychotic content.
  • Substance use: alcohol and illicit substance use commonly disrupts medication adherence both directly (forgetting when intoxicated) and indirectly (the lifestyle associated with active substance use conflicts with regular medication management).

The consequences of medication non-adherence

Non-adherence typically leads to relapse. Relapse in schizophrenia spectrum conditions generally means a return or escalation of psychotic symptoms, which in turn affects functioning across all domains — housing stability, community safety, relationships with support networks and service providers and the person’s overall situation. Each relapse may be associated with further deterioration of the baseline level of functioning. The cycle of partial adherence, relapse, hospitalisation, stabilisation and community re-entry is a clinically well-recognised pattern that must be documented in the Functional Capacity Assessment as a functional reality affecting the person’s long-term trajectory.

Involuntary treatment in Australia: Community Treatment Orders and depot medication

Where a person with schizophrenia or schizoaffective disorder consistently fails to adhere to medication and experiences repeated relapse as a result, the treating psychiatrist may apply to the relevant state or territory Mental Health Tribunal for a Community Treatment Order (CTO). Understanding what a CTO is, what it requires and what its functional implications are is clinically relevant for the Functional Capacity Assessment.

What is a Community Treatment Order?

A Community Treatment Order is a legal order made under state or territory mental health legislation that authorises a public mental health service to provide compulsory treatment to a person with a serious mental illness while the person is living in the community rather than in hospital. Each Australian state and territory has its own mental health legislation governing CTOs. The relevant Acts include, for example, the Mental Health Act 2007 in New South Wales, the Mental Health and Wellbeing Act 2022 in Victoria, the Mental Health Act 2016 in Queensland and comparable legislation in South Australia, Western Australia, Tasmania, the Northern Territory and the Australian Capital Territory.

A CTO generally requires the person to comply with a treatment plan that specifies the medication to be taken, the frequency and setting of administration and the appointments to be attended. CTOs can be made for a period of up to 12 months and can be renewed. Non-compliance with a CTO can result in the person being returned to an inpatient facility for involuntary treatment. CTO use in Australia is high by international standards, with Victoria having one of the highest rates of CTO use in the world.

The decision to make a CTO is made by the Mental Health Tribunal and requires that the person has a mental illness, that the proposed treatment is likely to be effective, that the CTO is the least restrictive alternative consistent with safe and effective care, that the person would benefit from the CTO and that there is a history of treatment refusal associated with relapse. Decisions can be reviewed and appealed.

Depot and long-acting injectable antipsychotic medication

Where medication non-adherence is a central clinical issue, the treating psychiatrist may prescribe a long-acting injectable antipsychotic medication, commonly referred to as a depot injection. Rather than requiring the person to take daily oral medication, a depot injection is administered by a clinician — typically a community mental health nurse — at a prescribed interval, most commonly every two to four weeks. The medication is released slowly into the body over the injection interval, providing consistent therapeutic levels without requiring daily adherence decisions.

Depot antipsychotic medications in current use in Australia include paliperidone palmitate (given monthly or every three months), aripiprazole monohydrate (given monthly), fluphenazine decanoate, haloperidol decanoate and zuclopenthixol decanoate (all given every one to four weeks), among others. For many people with schizophrenia spectrum conditions, depot medication represents a clinically important intervention that reduces the relapse cycle associated with oral medication non-adherence.

Where a person is prescribed depot medication, the Functional Capacity Assessment should document the medication type and interval, the location of administration, whether attendance is voluntary or under a CTO, and the functional implications of the medication schedule for the person’s daily routine. The fortnightly or monthly appointment for depot administration may require support worker assistance with transport, planning and attendance, which has direct implications for NDIS support planning.

Functional implications of CTOs for daily life

Being subject to a CTO has specific functional implications that the Functional Capacity Assessment must document. These include the mandatory nature of treatment appointments which structures the person’s weekly or monthly schedule; the legal framework which can generate anxiety and distress in some people; the risk of involuntary hospitalisation if the person misses appointments or refuses medication, creating a context of potential acute disruption; and the relationship between the compulsory treatment regime and the person’s autonomy, motivation and engagement with their recovery. Where a person has a history of non-compliance with CTOs and of being returned to hospital involuntarily, the pattern and its functional consequences must be specifically documented.

How schizoaffective disorder affects daily functioning

The functional impact of schizoaffective disorder reflects the combined impairments of its psychotic and mood components. This combination produces a more pervasive and more variable pattern of functional impairment than either schizophrenia or mood disorder alone.

Psychotic symptoms and their functional impact

Hallucinations in schizoaffective disorder most commonly involve hearing voices. The functional impact of auditory hallucinations depends on their content, frequency, intensity and the person’s capacity to manage them. Voices that comment on the person’s actions, issue commands or are highly distressing significantly impair concentration, initiation of daily tasks and capacity to engage safely in the community. During acute psychotic episodes, the person may be unable to perform any purposeful daily activity.

Delusions, which are fixed false beliefs maintained despite contradictory evidence, affect functioning through the behaviour they generate. Persecutory delusions — the belief that one is being watched, followed or harmed — can produce profound social withdrawal, inability to leave the home, refusal of services and treatment and significant agitation and fear. Grandiose delusions can drive impulsive, risky behaviour including financial decisions, social confrontations and unsafe activities.

Disorganised thinking, which presents as tangential or incoherent speech and difficulty maintaining a logical train of thought, directly affects the person’s capacity to manage daily communications, navigate services, follow instructions, manage finances and maintain employment or education.

Negative symptoms and their functional impact

Negative symptoms — including flat or blunted affect, avolition (markedly reduced motivation and goal-directed behaviour), alogia (reduced spontaneous speech) and anhedonia (reduced capacity for pleasure) — are frequently the most disabling features of schizoaffective disorder for daily functioning and are consistently underrepresented in NDIS assessments. Avolition directly affects the person’s capacity to initiate and sustain self-care tasks, maintain household routines, attend appointments, engage in therapy and pursue employment or community activities. Unlike the positive symptoms of psychosis, which tend to respond to antipsychotic medication, negative symptoms are often more persistent and more treatment-resistant.

Mood symptoms and their functional impact

In the bipolar type

During manic episodes, the person may present with markedly elevated or irritable mood, dramatically increased energy and activity, decreased need for sleep, racing thoughts, pressured speech, inflated self-esteem and significantly impaired judgement. The functional consequences of manic episodes include impulsive financial decisions, destruction of relationships and social supports, unsafe sexual behaviour, involvement with the criminal justice system due to disinhibited behaviour and, in severe cases, inability to manage any aspect of daily life safely. The aftermath of a manic episode frequently involves the collapse of the relationships, financial stability and social situation that were disrupted during the episode.

In the depressive type and depressive phases

During major depressive episodes, the person experiences pervasive low mood, loss of interest or pleasure in almost all activities, significant changes in sleep and appetite, fatigue and loss of energy, psychomotor retardation or agitation, difficulty concentrating and, frequently, suicidal ideation. In the context of schizoaffective disorder, the depressive phase is compounded by the concurrent presence of psychotic symptoms, creating a clinical picture of profound helplessness, hopelessness and perceptual distortion that is more severe than depression without psychosis.

Cognitive impairment

Cognitive impairment is a core feature of schizoaffective disorder and is present to a degree that exceeds what would be expected from mood disorder alone. Areas of cognitive function commonly affected include working memory, processing speed, attention and sustained concentration, learning and memory consolidation and executive functioning including planning, problem solving and cognitive flexibility. These cognitive impairments are present across all phases of the illness, not only during acute episodes. They directly affect the person’s capacity to manage daily activities, navigate services, maintain employment and live independently.

Medication side effects

The pharmacological management of schizoaffective disorder typically involves a combination of antipsychotic medication and mood stabilisers or antidepressants. Many antipsychotic medications produce significant side effects that themselves affect daily functioning. These include sedation and fatigue that affect concentration and sustained activity, weight gain and metabolic changes that affect physical health and capacity, extrapyramidal effects including muscle stiffness and restlessness, and tardive dyskinesia in some cases. Medication side effects must be assessed and documented in the Functional Capacity Assessment as contributors to the overall functional impairment picture.

The fluctuating course of schizoaffective disorder

Schizoaffective disorder typically follows a fluctuating course, with periods of acute illness, partial remission and periods of relative stability. This fluctuation has direct implications for Functional Capacity Assessment. An assessment completed during a period of relative stability will not capture the functional picture during acute episodes, which may involve a complete inability to perform any daily living activities, significant safety risks and the need for emergency or inpatient care. An assessment completed during an acute episode may not capture the person’s capacity during more stable periods.

The Functional Capacity Assessment must specifically document the person’s functional capacity across the full range of their illness course, including during acute episodes, during partial remission and during stable periods. This includes documenting the frequency, duration and functional consequences of acute episodes and the level of support required across each phase. The NDIS plan must fund support that is adequate for the most demanding phases of the illness, not only for the best periods.

Schizoaffective disorder and NDIS access

Schizoaffective disorder is not included in NDIS Condition List A or List B by name. NDIS access must be established through functional evidence demonstrating that the condition results in substantially reduced functional capacity. Given the severity and chronicity of schizoaffective disorder, the condition frequently meets the NDIS substantially reduced functional capacity threshold. The primary challenge is documenting the functional impairment comprehensively and establishing that the condition is permanent or likely to be permanent.

Schizoaffective disorder is a chronic, lifelong condition. While symptoms can be managed and quality of life improved with appropriate treatment, the condition does not resolve. The permanence criterion for NDIS access is generally met where the diagnosis is well-established, the illness course is documented over time and the treating psychiatrist’s evidence supports the chronic nature of the condition.

What the Functional Capacity Assessment must establish for NDIS access

The diagnosis is confirmed by a psychiatrist or appropriately qualified clinician, meets DSM-5 criteria and identifies the subtype (bipolar or depressive type).

The condition is chronic and permanent or likely to be permanent, documented through the clinical history and trajectory of the illness.

The condition results in substantially reduced functional capacity across one or more NDIS functional domains.

The functional impairment is documented across the full illness course, not only at best periods.

The support requirements across acute, partial remission and stable phases are specifically documented.

The functional impact of co-occurring conditions including substance use, housing instability and the side effects of medication is addressed.

What a Functional Capacity Assessment covers for schizoaffective disorder

  • Assessment of psychotic symptoms and their functional impact, specifically documenting how hallucinations, delusions, disorganised thinking and negative symptoms affect the person’s capacity across each NDIS functional domain
  • Assessment of mood symptoms and their functional impact across both manic and depressive phases in the bipolar type, and across depressive phases in the depressive type
  • Assessment of cognitive impairment and its functional impact on daily task management, service engagement, employment capacity and independent living
  • Assessment of medication effects and their contribution to functional impairment
  • Documentation of the illness course, including the frequency and duration of acute episodes, the functional picture at each phase and the support required during each phase
  • Assessment of self-care and activities of daily living across all phases of the illness, with specific documentation of what the person can manage independently, what requires prompting and what requires direct assistance
  • Assessment of the capacity for independent living, including financial management, household management and medication management
  • Assessment of safety, including the risk of self-harm, suicidality, risk to others during acute psychotic or manic episodes and vulnerability in the community
  • Assessment of community participation and social functioning across all phases of the illness
  • Assessment of any co-occurring conditions, including substance use, physical health conditions and other psychiatric comorbidities
  • Assessment of the impact of social circumstances including housing stability, support network and access to mental health services

The 2026 NDIS context

The Securing the NDIS for Future Generations Bill 2026, introduced to Parliament on 14 May 2026, strengthens the requirement that NDIS supports must have a direct causal connection to the eligible impairment. For people with schizoaffective disorder, this means the Functional Capacity Assessment must clearly document how the specific features of the schizoaffective disorder presentation — its psychotic symptoms, mood symptoms, negative symptoms, cognitive impairment and fluctuating course — cause the functional impairments documented and the support requirements identified. A generic psychosocial disability assessment without specific reference to the schizoaffective disorder presentation and its functional mechanisms will not provide adequate evidence under the current and forthcoming framework.

Who can refer?

Referrals are accepted from participants and families, support coordinators, psychiatrists, psychologists, GPs, community mental health teams and legal representatives involved in NDIS appeals. Sina OT has completed Functional Capacity Assessments for individuals with psychosocial disability across a range of presentations across Adelaide, Melbourne and Sydney. All assessments are completed in person in the participant’s home and community environment.

Refer to Sina OT

Sina OT is an independent Occupational Therapy practice providing Functional Capacity Assessments across Adelaide, Melbourne and Sydney.

Sina OT has completed Functional Capacity Assessments for individuals with acquired brain injury across a range of causes and presentations. All assessments are completed in person in the participant’s home and community environment by a registered Occupational Therapist.

Services are available in English and Farsi (Persian).

Related Insight Articles

Functional Capacity Assessment for Stroke

Functional Capacity Assessment for Stroke

Stroke is one of the leading causes of disability in Australia. Each year approximately 56,000 Australians have a stroke and more than 430,000 Australians live with the long-term effects of stroke. For people who are under 65 at the time of their stroke, the NDIS is the primary pathway to accessing disability support funding. The functional consequences of stroke are wide-ranging, highly individual and extend far beyond the physical impairments that are most visible to others. A Functional Capacity Assessment is the cornerstone of NDIS access and planning for stroke survivors.

Functional Capacity Assessment for Multiple Sclerosis

Functional Capacity Assessment for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune condition in which the immune system attacks the myelin sheath that protects nerve fibres in the brain and spinal cord. Australia has one of the highest rates of MS in the world, with more than 33,000 Australians living with the condition. MS typically affects people in their most productive years, with diagnosis most common between the ages of 20 and 40. The functional impact of MS is highly variable, both between individuals and within the same individual over time, producing specific challenges for NDIS planning that require comprehensive, condition-specific assessment.

Functional Capacity Assessment for Autism Spectrum Disorder

Functional Capacity Assessment for Autism Spectrum Disorder

Autism Spectrum Disorder (ASD) affects an estimated one in 40 Australians. It is one of the most common presentations in the NDIS and one of the most complex to assess for funding purposes. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies ASD into three severity levels, each describing a different level of support required. Understanding what these levels mean clinically, how they interact with NDIS eligibility and what a Functional Capacity Assessment provides at each level is essential knowledge for anyone navigating the NDIS with an ASD diagnosis.